Review





Similar Products

hsp90  (Proteintech)
96
Proteintech hsp90
Caffeic acid effectively inhibits the migration and viability of ESCC cells. (a) The candidate drugs that bind to ATP6V0D2 stored in DSigDB. (b) The binding affinity between ATP6V0D2 and drug targets predicted by molecular docking simulation. (c) The molecular docking diagram between ATP6V0D2 and caffeic acid. (d) Cellular thermal shift assay of ATP6V0D2 with caffeic acid in HEK-293T cells. (e) Wound-healing assay of KYSE-30 cells treated with caffeic acid. Scale bar, 200 μm ( n = 3). (f) Quantification of KYSE-30 cells migration area. n = 3 for each group. *** P < 0.001, **** P < 0.0001, two-way ANOVA. (g) Wound-healing assay of KYSE-510 cells treated with caffeic acid. Scale bar, 200 μm ( n = 6). (h) Quantification of KYSE-510 cell migration area. n = 6 for each group. ns, P > 0.05, ** P < 0.01, **** P < 0.0001, two-way ANOVA. (i–j) Effects of caffeic acid on cell viability of KYSE-30 and KYSE-510 cells for 3 d. n = 6 for KYSE-30 cells, n = 8 for KYSE-510 cells. **** P < 0.0001, Student’s t test. (k) Apoptosis analysis of KYSE-30 and KYSE-510 cells treated with DMSO or caffeic acid. n = 3 for each group. ns, P > 0.05, * P < 0.05, Student’s t test. (l–m) Cell cycle distribution of KYSE-30 (l) and KYSE-510 (m) cells following DMSO or caffeic acid treatment. n = 3 for each group. ns, P > 0.05, * P < 0.05, ** P < 0.01, Student’s t test.
Hsp90, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hsp90+antibody/HSP90+Antibody/pmc13682402-6-0-2
Average 96 stars, based on 1 article reviews
hsp90 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier
hsp90  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology hsp90
Caffeic acid effectively inhibits the migration and viability of ESCC cells. (a) The candidate drugs that bind to ATP6V0D2 stored in DSigDB. (b) The binding affinity between ATP6V0D2 and drug targets predicted by molecular docking simulation. (c) The molecular docking diagram between ATP6V0D2 and caffeic acid. (d) Cellular thermal shift assay of ATP6V0D2 with caffeic acid in HEK-293T cells. (e) Wound-healing assay of KYSE-30 cells treated with caffeic acid. Scale bar, 200 μm ( n = 3). (f) Quantification of KYSE-30 cells migration area. n = 3 for each group. *** P < 0.001, **** P < 0.0001, two-way ANOVA. (g) Wound-healing assay of KYSE-510 cells treated with caffeic acid. Scale bar, 200 μm ( n = 6). (h) Quantification of KYSE-510 cell migration area. n = 6 for each group. ns, P > 0.05, ** P < 0.01, **** P < 0.0001, two-way ANOVA. (i–j) Effects of caffeic acid on cell viability of KYSE-30 and KYSE-510 cells for 3 d. n = 6 for KYSE-30 cells, n = 8 for KYSE-510 cells. **** P < 0.0001, Student’s t test. (k) Apoptosis analysis of KYSE-30 and KYSE-510 cells treated with DMSO or caffeic acid. n = 3 for each group. ns, P > 0.05, * P < 0.05, Student’s t test. (l–m) Cell cycle distribution of KYSE-30 (l) and KYSE-510 (m) cells following DMSO or caffeic acid treatment. n = 3 for each group. ns, P > 0.05, * P < 0.05, ** P < 0.01, Student’s t test.
Hsp90, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hsp90+antibody/HSP+90%CE%B1%2F%CE%B2+Antibody/pm42870295-75-64-65
Average 96 stars, based on 1 article reviews
hsp90 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier
hsp90  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc hsp90
Caffeic acid effectively inhibits the migration and viability of ESCC cells. (a) The candidate drugs that bind to ATP6V0D2 stored in DSigDB. (b) The binding affinity between ATP6V0D2 and drug targets predicted by molecular docking simulation. (c) The molecular docking diagram between ATP6V0D2 and caffeic acid. (d) Cellular thermal shift assay of ATP6V0D2 with caffeic acid in HEK-293T cells. (e) Wound-healing assay of KYSE-30 cells treated with caffeic acid. Scale bar, 200 μm ( n = 3). (f) Quantification of KYSE-30 cells migration area. n = 3 for each group. *** P < 0.001, **** P < 0.0001, two-way ANOVA. (g) Wound-healing assay of KYSE-510 cells treated with caffeic acid. Scale bar, 200 μm ( n = 6). (h) Quantification of KYSE-510 cell migration area. n = 6 for each group. ns, P > 0.05, ** P < 0.01, **** P < 0.0001, two-way ANOVA. (i–j) Effects of caffeic acid on cell viability of KYSE-30 and KYSE-510 cells for 3 d. n = 6 for KYSE-30 cells, n = 8 for KYSE-510 cells. **** P < 0.0001, Student’s t test. (k) Apoptosis analysis of KYSE-30 and KYSE-510 cells treated with DMSO or caffeic acid. n = 3 for each group. ns, P > 0.05, * P < 0.05, Student’s t test. (l–m) Cell cycle distribution of KYSE-30 (l) and KYSE-510 (m) cells following DMSO or caffeic acid treatment. n = 3 for each group. ns, P > 0.05, * P < 0.05, ** P < 0.01, Student’s t test.
Hsp90, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hsp90+antibody/HSP90+Antibody/pmc13655318-356-42-43
Average 96 stars, based on 1 article reviews
hsp90 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier
anti hsp90  (Proteintech)
96
Proteintech anti hsp90
Caffeic acid effectively inhibits the migration and viability of ESCC cells. (a) The candidate drugs that bind to ATP6V0D2 stored in DSigDB. (b) The binding affinity between ATP6V0D2 and drug targets predicted by molecular docking simulation. (c) The molecular docking diagram between ATP6V0D2 and caffeic acid. (d) Cellular thermal shift assay of ATP6V0D2 with caffeic acid in HEK-293T cells. (e) Wound-healing assay of KYSE-30 cells treated with caffeic acid. Scale bar, 200 μm ( n = 3). (f) Quantification of KYSE-30 cells migration area. n = 3 for each group. *** P < 0.001, **** P < 0.0001, two-way ANOVA. (g) Wound-healing assay of KYSE-510 cells treated with caffeic acid. Scale bar, 200 μm ( n = 6). (h) Quantification of KYSE-510 cell migration area. n = 6 for each group. ns, P > 0.05, ** P < 0.01, **** P < 0.0001, two-way ANOVA. (i–j) Effects of caffeic acid on cell viability of KYSE-30 and KYSE-510 cells for 3 d. n = 6 for KYSE-30 cells, n = 8 for KYSE-510 cells. **** P < 0.0001, Student’s t test. (k) Apoptosis analysis of KYSE-30 and KYSE-510 cells treated with DMSO or caffeic acid. n = 3 for each group. ns, P > 0.05, * P < 0.05, Student’s t test. (l–m) Cell cycle distribution of KYSE-30 (l) and KYSE-510 (m) cells following DMSO or caffeic acid treatment. n = 3 for each group. ns, P > 0.05, * P < 0.05, ** P < 0.01, Student’s t test.
Anti Hsp90, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hsp90+antibody/HSP90+Antibody/10__1038_slash_s41467___026___78424___w-288-15-16
Average 96 stars, based on 1 article reviews
anti hsp90 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier
anti spata2  (Proteintech)
96
Proteintech anti spata2
Caffeic acid effectively inhibits the migration and viability of ESCC cells. (a) The candidate drugs that bind to ATP6V0D2 stored in DSigDB. (b) The binding affinity between ATP6V0D2 and drug targets predicted by molecular docking simulation. (c) The molecular docking diagram between ATP6V0D2 and caffeic acid. (d) Cellular thermal shift assay of ATP6V0D2 with caffeic acid in HEK-293T cells. (e) Wound-healing assay of KYSE-30 cells treated with caffeic acid. Scale bar, 200 μm ( n = 3). (f) Quantification of KYSE-30 cells migration area. n = 3 for each group. *** P < 0.001, **** P < 0.0001, two-way ANOVA. (g) Wound-healing assay of KYSE-510 cells treated with caffeic acid. Scale bar, 200 μm ( n = 6). (h) Quantification of KYSE-510 cell migration area. n = 6 for each group. ns, P > 0.05, ** P < 0.01, **** P < 0.0001, two-way ANOVA. (i–j) Effects of caffeic acid on cell viability of KYSE-30 and KYSE-510 cells for 3 d. n = 6 for KYSE-30 cells, n = 8 for KYSE-510 cells. **** P < 0.0001, Student’s t test. (k) Apoptosis analysis of KYSE-30 and KYSE-510 cells treated with DMSO or caffeic acid. n = 3 for each group. ns, P > 0.05, * P < 0.05, Student’s t test. (l–m) Cell cycle distribution of KYSE-30 (l) and KYSE-510 (m) cells following DMSO or caffeic acid treatment. n = 3 for each group. ns, P > 0.05, * P < 0.05, ** P < 0.01, Student’s t test.
Anti Spata2, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hsp90+antibody/HSP90+Antibody/pm42837793-105-8-9
Average 96 stars, based on 1 article reviews
anti spata2 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier
ca n a hsp90 alpha beta f 8 santa cruz biotechnology cat sc 13119  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology ca n a hsp90 alpha beta f 8 santa cruz biotechnology cat sc 13119
Caffeic acid effectively inhibits the migration and viability of ESCC cells. (a) The candidate drugs that bind to ATP6V0D2 stored in DSigDB. (b) The binding affinity between ATP6V0D2 and drug targets predicted by molecular docking simulation. (c) The molecular docking diagram between ATP6V0D2 and caffeic acid. (d) Cellular thermal shift assay of ATP6V0D2 with caffeic acid in HEK-293T cells. (e) Wound-healing assay of KYSE-30 cells treated with caffeic acid. Scale bar, 200 μm ( n = 3). (f) Quantification of KYSE-30 cells migration area. n = 3 for each group. *** P < 0.001, **** P < 0.0001, two-way ANOVA. (g) Wound-healing assay of KYSE-510 cells treated with caffeic acid. Scale bar, 200 μm ( n = 6). (h) Quantification of KYSE-510 cell migration area. n = 6 for each group. ns, P > 0.05, ** P < 0.01, **** P < 0.0001, two-way ANOVA. (i–j) Effects of caffeic acid on cell viability of KYSE-30 and KYSE-510 cells for 3 d. n = 6 for KYSE-30 cells, n = 8 for KYSE-510 cells. **** P < 0.0001, Student’s t test. (k) Apoptosis analysis of KYSE-30 and KYSE-510 cells treated with DMSO or caffeic acid. n = 3 for each group. ns, P > 0.05, * P < 0.05, Student’s t test. (l–m) Cell cycle distribution of KYSE-30 (l) and KYSE-510 (m) cells following DMSO or caffeic acid treatment. n = 3 for each group. ns, P > 0.05, * P < 0.05, ** P < 0.01, Student’s t test.
Ca N A Hsp90 Alpha Beta F 8 Santa Cruz Biotechnology Cat Sc 13119, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hsp90+antibody/HSP+90%CE%B1%2F%CE%B2+Antibody/pm42814571-690-61-66
Average 96 stars, based on 1 article reviews
ca n a hsp90 alpha beta f 8 santa cruz biotechnology cat sc 13119 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier
636 mouse anti hsp90 alpha beta santa cruz biotechnology  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology 636 mouse anti hsp90 alpha beta santa cruz biotechnology
Caffeic acid effectively inhibits the migration and viability of ESCC cells. (a) The candidate drugs that bind to ATP6V0D2 stored in DSigDB. (b) The binding affinity between ATP6V0D2 and drug targets predicted by molecular docking simulation. (c) The molecular docking diagram between ATP6V0D2 and caffeic acid. (d) Cellular thermal shift assay of ATP6V0D2 with caffeic acid in HEK-293T cells. (e) Wound-healing assay of KYSE-30 cells treated with caffeic acid. Scale bar, 200 μm ( n = 3). (f) Quantification of KYSE-30 cells migration area. n = 3 for each group. *** P < 0.001, **** P < 0.0001, two-way ANOVA. (g) Wound-healing assay of KYSE-510 cells treated with caffeic acid. Scale bar, 200 μm ( n = 6). (h) Quantification of KYSE-510 cell migration area. n = 6 for each group. ns, P > 0.05, ** P < 0.01, **** P < 0.0001, two-way ANOVA. (i–j) Effects of caffeic acid on cell viability of KYSE-30 and KYSE-510 cells for 3 d. n = 6 for KYSE-30 cells, n = 8 for KYSE-510 cells. **** P < 0.0001, Student’s t test. (k) Apoptosis analysis of KYSE-30 and KYSE-510 cells treated with DMSO or caffeic acid. n = 3 for each group. ns, P > 0.05, * P < 0.05, Student’s t test. (l–m) Cell cycle distribution of KYSE-30 (l) and KYSE-510 (m) cells following DMSO or caffeic acid treatment. n = 3 for each group. ns, P > 0.05, * P < 0.05, ** P < 0.01, Student’s t test.
636 Mouse Anti Hsp90 Alpha Beta Santa Cruz Biotechnology, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hsp90+antibody/HSP+90%CE%B1%2F%CE%B2+Antibody/pm42805170-926-42-46
Average 96 stars, based on 1 article reviews
636 mouse anti hsp90 alpha beta santa cruz biotechnology - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier
60318 1 ig  (Proteintech)
96
Proteintech 60318 1 ig
Caffeic acid effectively inhibits the migration and viability of ESCC cells. (a) The candidate drugs that bind to ATP6V0D2 stored in DSigDB. (b) The binding affinity between ATP6V0D2 and drug targets predicted by molecular docking simulation. (c) The molecular docking diagram between ATP6V0D2 and caffeic acid. (d) Cellular thermal shift assay of ATP6V0D2 with caffeic acid in HEK-293T cells. (e) Wound-healing assay of KYSE-30 cells treated with caffeic acid. Scale bar, 200 μm ( n = 3). (f) Quantification of KYSE-30 cells migration area. n = 3 for each group. *** P < 0.001, **** P < 0.0001, two-way ANOVA. (g) Wound-healing assay of KYSE-510 cells treated with caffeic acid. Scale bar, 200 μm ( n = 6). (h) Quantification of KYSE-510 cell migration area. n = 6 for each group. ns, P > 0.05, ** P < 0.01, **** P < 0.0001, two-way ANOVA. (i–j) Effects of caffeic acid on cell viability of KYSE-30 and KYSE-510 cells for 3 d. n = 6 for KYSE-30 cells, n = 8 for KYSE-510 cells. **** P < 0.0001, Student’s t test. (k) Apoptosis analysis of KYSE-30 and KYSE-510 cells treated with DMSO or caffeic acid. n = 3 for each group. ns, P > 0.05, * P < 0.05, Student’s t test. (l–m) Cell cycle distribution of KYSE-30 (l) and KYSE-510 (m) cells following DMSO or caffeic acid treatment. n = 3 for each group. ns, P > 0.05, * P < 0.05, ** P < 0.01, Student’s t test.
60318 1 Ig, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hsp90+antibody/HSP90+Antibody/10__1038_slash_s41419___026___09265___0-38-10-9
Average 96 stars, based on 1 article reviews
60318 1 ig - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

Image Search Results


Caffeic acid effectively inhibits the migration and viability of ESCC cells. (a) The candidate drugs that bind to ATP6V0D2 stored in DSigDB. (b) The binding affinity between ATP6V0D2 and drug targets predicted by molecular docking simulation. (c) The molecular docking diagram between ATP6V0D2 and caffeic acid. (d) Cellular thermal shift assay of ATP6V0D2 with caffeic acid in HEK-293T cells. (e) Wound-healing assay of KYSE-30 cells treated with caffeic acid. Scale bar, 200 μm ( n = 3). (f) Quantification of KYSE-30 cells migration area. n = 3 for each group. *** P < 0.001, **** P < 0.0001, two-way ANOVA. (g) Wound-healing assay of KYSE-510 cells treated with caffeic acid. Scale bar, 200 μm ( n = 6). (h) Quantification of KYSE-510 cell migration area. n = 6 for each group. ns, P > 0.05, ** P < 0.01, **** P < 0.0001, two-way ANOVA. (i–j) Effects of caffeic acid on cell viability of KYSE-30 and KYSE-510 cells for 3 d. n = 6 for KYSE-30 cells, n = 8 for KYSE-510 cells. **** P < 0.0001, Student’s t test. (k) Apoptosis analysis of KYSE-30 and KYSE-510 cells treated with DMSO or caffeic acid. n = 3 for each group. ns, P > 0.05, * P < 0.05, Student’s t test. (l–m) Cell cycle distribution of KYSE-30 (l) and KYSE-510 (m) cells following DMSO or caffeic acid treatment. n = 3 for each group. ns, P > 0.05, * P < 0.05, ** P < 0.01, Student’s t test.

Journal: Epigenetics

Article Title: Diverse patterns of transcriptional regulation and epigenetic reprogramming within PMDs contribute to ESCC progression by regulating EMT and immunosuppression

doi: 10.1080/15592294.2026.2745292

Figure Lengend Snippet: Caffeic acid effectively inhibits the migration and viability of ESCC cells. (a) The candidate drugs that bind to ATP6V0D2 stored in DSigDB. (b) The binding affinity between ATP6V0D2 and drug targets predicted by molecular docking simulation. (c) The molecular docking diagram between ATP6V0D2 and caffeic acid. (d) Cellular thermal shift assay of ATP6V0D2 with caffeic acid in HEK-293T cells. (e) Wound-healing assay of KYSE-30 cells treated with caffeic acid. Scale bar, 200 μm ( n = 3). (f) Quantification of KYSE-30 cells migration area. n = 3 for each group. *** P < 0.001, **** P < 0.0001, two-way ANOVA. (g) Wound-healing assay of KYSE-510 cells treated with caffeic acid. Scale bar, 200 μm ( n = 6). (h) Quantification of KYSE-510 cell migration area. n = 6 for each group. ns, P > 0.05, ** P < 0.01, **** P < 0.0001, two-way ANOVA. (i–j) Effects of caffeic acid on cell viability of KYSE-30 and KYSE-510 cells for 3 d. n = 6 for KYSE-30 cells, n = 8 for KYSE-510 cells. **** P < 0.0001, Student’s t test. (k) Apoptosis analysis of KYSE-30 and KYSE-510 cells treated with DMSO or caffeic acid. n = 3 for each group. ns, P > 0.05, * P < 0.05, Student’s t test. (l–m) Cell cycle distribution of KYSE-30 (l) and KYSE-510 (m) cells following DMSO or caffeic acid treatment. n = 3 for each group. ns, P > 0.05, * P < 0.05, ** P < 0.01, Student’s t test.

Article Snippet: HSP90 , Proteintech , 13171–1-AP.

Techniques: Migration, Binding Assay, Docking Assay, Thermal Shift Assay, Wound Healing Assay, Analysis, Significance Assay

Journal: Epigenetics

Article Title: Diverse patterns of transcriptional regulation and epigenetic reprogramming within PMDs contribute to ESCC progression by regulating EMT and immunosuppression

doi: 10.1080/15592294.2026.2745292

Figure Lengend Snippet:

Article Snippet: HSP90 , Proteintech , 13171–1-AP.

Techniques: